Dr. Catherine Broome

Hematology
3800 Reservoir Rd Nw, 
Washington, DC 
3800 Reservoir Rd Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Catherine Broome is a Hematologist in Washington, Washington, D.c.. Dr. Broome is rated as an Experienced provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Autoimmune Hemolytic Anemia, Chronic B-Cell Leukemia (CBCL), Thrombocytopenia, Bone Marrow Aspiration, and Splenectomy.

Her clinical research consists of co-authoring 36 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in DC
Hospital Affiliations
Medstar Georgetown University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

MGMC LLC
3800 Reservoir Rd Nw, Washington, DC 20007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (LUMINA 2)
A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (LUMINA 2)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rilzabrutinib
Study Phase: Phase 2
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Other, Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Procedure, Other
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
Enrollment Status: Terminated
Publish Date: May 25, 2023
Intervention Type: Biological
Study Drugs: Thrombosomes, Liquid-Stored Platelets
Study Phase: Phase 2
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: May 25, 2023
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 3
A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
Enrollment Status: Completed
Publish Date: May 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 2
View 9 Less Clinical Trials

36 Total Publications

Dual therapy: danicopan as add-on therapy to C5 inhibitors.
Dual therapy: danicopan as add-on therapy to C5 inhibitors.
Journal: Clinical advances in hematology & oncology : H&O
Published: July 01, 2025
Similar Doctors
Andrew S. Mener
Advanced in Hemochromatosis
Dr. Andrew S. Mener
Hematology | Hematology Oncology | Oncology
Advanced in Hemochromatosis
Dr. Andrew S. Mener
Hematology | Hematology Oncology | Oncology

Maryland Oncology Hematology

10710 Charter Drive, Suite G020, Suite G020, 
Columbia, MD 
 (22.9 miles away)
410-964-2212
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Mener, M.D. has experience treating a wide range of adult hematologic and oncologic disorders, with a particular interest in treating breast, lung, gastrointestinal and hematologic malignancies. He takes great pride in delivering personalized, compassionate care and strives to effectively explain complex treatment options to his patients. He strongly believes in the importance of treating each and every patient as an individual. Learn more at marylandoncology.com. Dr. Mener is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Severe Congenital Neutropenia.

Advanced in Hemochromatosis
Dr. Sadaf Taimur
Hematology Oncology | Hematology | Oncology
Advanced in Hemochromatosis
Dr. Sadaf Taimur
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

7704 Matapeake Business Dr, Suite 200, 
Brandywine, MD 
 (19.5 miles away)
301-812-3900
Languages Spoken:
English, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sadaf Taimur is a Hematologist Oncology specialist and a Hematologist in Brandywine, Maryland. Dr. Taimur is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Paget Disease of the Breast, and Pulmonary Embolism. Dr. Taimur is currently accepting new patients.

Advanced in Hemochromatosis
Dr. Nouman Asif
Hematology Oncology | Hematology | Oncology
Advanced in Hemochromatosis
Dr. Nouman Asif
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

7211 Bank Ct, Suite 150, 
Frederick, MD 
 (37.4 miles away)
301-418-6611
Languages Spoken:
English, Arabic, Hindi, Punjabi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Nouman Asif is a Hematologist Oncology specialist and a Hematologist in Frederick, Maryland. Dr. Asif is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Anemia, and Thrombocytopenia. Dr. Asif is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Broome's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 18 Advanced Conditions
View All 63 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile